13F Holdings
中文EN

ESLA Estrella Immunopharma, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1844417 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.7%
TTM EPS YoY20.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-484.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets936.1%
Debt / equity—
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-143.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-06-30FY20232023-06-30FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$10.25M$4.11M$10.45M——
SG&A expense$2.81M$3.20M$663,190——
Operating income-$13.06M-$7.31M-$11.11M-$1.57M-$249,146
Pretax income-$13.06M-$7.31M-$11.11M-$915,456-$247,718
Income tax$838$1,625—$80,648$0
Net income-$13.06M-$7.31M-$11.11M-$996,104-$247,718
EPS (basic)-0.35-0.27-36.35——
EPS (diluted)-0.35-0.27-36.35——
Weighted avg. shares (diluted)36.82M27.10M305,748—1.18M
Banking
Deposits$1.50M$1.50M———
Balance sheet
Cash & equivalents$1.38M$4.17M$2.48M$2.88M$478,868
Receivables——$273,066——
Current assets$1.68M$4.45M$2.75M$52,427$616,034
Total assets$3.18M$4.45M$3.03M$9.72M$45.80M
Current liabilities$13.54M$180,701$9.76M$1.07M$73,154
Total liabilities$13.54M$180,701$9.77M$2.65M$1.62M
Shareholders' equity-$10.37M$4.27M-$11.74M-$6.48M-$1.01M
Shares outstanding37.97M36.61M978,2431.42M1.42M
Cash flow statement
Operating cash flow-$1.79M-$16.07M-$1.34M-$1.04M-$316,158
Investing cash flow—$4.96M-$273,066$36.17M-$45.19M
Financing cash flow$2.25M$12.79M—-$35.56M$45.98M
Stock-based compensation$618,974$1.19M$409,595——

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.